var title_f23_13_23760="Forearm anatomy 1";
var content_f23_13_23760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Forearm anatomy: Interosseous membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Force applied to one bone is transmitted to the other bone by the interosseous membrane. The attachment and the fibers of the interosseous membrane are such that there is no attachment to the distal radius.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23760=[""].join("\n");
var outline_f23_13_23760=null;
var title_f23_13_23761="Hydrops with ascites and pleural effusion";
var content_f23_13_23761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Hydrops",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound images demonstrating (A) ascites (arrow). Coronal T2w MRI image demonstrates (B) a small pleural effusion (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy I Bulas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23761=[""].join("\n");
var outline_f23_13_23761=null;
var title_f23_13_23762="Memorial symptom assessment";
var content_f23_13_23762=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Memorial Symptom Assessment Scale - Short Form [MSAS-SF]",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 788px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23762=[""].join("\n");
var outline_f23_13_23762=null;
var title_f23_13_23763="Multiseptated cervicothoracic hydrosyringomyelia";
var content_f23_13_23763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Multiseptated cervicothoracic hydrosyringomyelia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiseptated hydrosyringomyelia spanning multiple cervicothoracic segments (asterisks) demonstrated on on T1 sagittal magnetic resonance imaging (MRI). The patient has Crouzon syndrome (craniofacial dysostosis type I).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Chaouki El-Khoury, BS, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23763=[""].join("\n");
var outline_f23_13_23763=null;
var title_f23_13_23764="Potassium bicarbonate and potassium chloride (effervescent): Patient drug information";
var content_f23_13_23764=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Potassium bicarbonate and potassium chloride (effervescent): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/37/22099?source=see_link\">",
"     see \"Potassium bicarbonate and potassium chloride (effervescent): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/3/37938?source=see_link\">",
"     see \"Potassium bicarbonate and potassium chloride (effervescent): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat low potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702764",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to potassium bicarbonate, potassium chloride, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703766",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If water pill is stopped, potassium will most often be stopped too. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695447",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       cup of water or juice and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12100 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-7146F32753-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23764=[""].join("\n");
var outline_f23_13_23764=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012855\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012854\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012859\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012860\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012862\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012857\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012858\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012863\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012864\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/37/22099?source=related_link\">",
"      Potassium bicarbonate and potassium chloride (effervescent): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/3/37938?source=related_link\">",
"      Potassium bicarbonate and potassium chloride (effervescent): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_13_23765="Desloratadine: Pediatric drug information";
var content_f23_13_23765=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Desloratadine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12934?source=see_link\">",
"    see \"Desloratadine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/41/44692?source=see_link\">",
"    see \"Desloratadine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clarinex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aerius&reg;;",
"     </li>",
"     <li>",
"      Aerius&reg; Kids;",
"     </li>",
"     <li>",
"      Desloratadine Allergy Control",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12934?source=see_link\">",
"      see \"Desloratadine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 months: 1 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 1-5 years: 1.25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years: 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal/hepatic impairment:",
"     </b>",
"     Administer dosage every other day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F157682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clarinex&reg;: 0.5 mg/mL (480 mL) [contains propylene glycol, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clarinex&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 2.5 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clarinex&reg;: 2.5 mg [DSC] [contains phenylalanine 1.4 mg/tablet; tutti frutti flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clarinex&reg;: 5 mg [DSC] [contains phenylalanine 2.9 mg/tablet; tutti frutti flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F157669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes syrup",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer without regard to food. Place RediTabs&reg; directly on the tongue; tablet will disintegrate immediately; may be taken with or without water",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; avoid excessive heat and moisture; RediTabs&reg; must be used immediately after removal from blister pack",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of nasal and non-nasal symptoms of allergic rhinitis; chronic idiopathic urticaria",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7258803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Clarinex&reg; may be confused with Celebrex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F157737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, emotional lability, fatigue, fever, headache, irritability, insomnia, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, appetite  increased, diarrhea, dyspepsia, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, maculopapular rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia Otic: Otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, epistaxis, pharyngitis, rhinorrhea, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Parasitic infection, varicella infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Hepatitis (rare), hyperbilirubinemia; hypersensitivity reactions (including anaphylaxis, dyspnea, edema, pruritus, rash, urticaria); liver enzymes increased, palpitations, psychomotor hyperactivity, seizures, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to desloratadine, loratadine, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A subset of the general population (7% in clinical trials) are slow metabolizers of desloratadine; the frequency of slow metabolism appears to be higher in African Americans; patients who are slow metabolizers may be more susceptible to dose-related side effects; use with caution in &ldquo;slow metabolizers.&rdquo; Use cautiously in patients who are also taking ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, or other drugs which may impair desloratadine's hepatic metabolism; although increased plasma levels of desloratadine have been observed, no adverse effects with concomitant administration have been reported, including QT interval prolongation which has occurred when similar antihistamines, terfenadine and astemizole, were combined with these agents. While less sedating than other antihistamines, desloratadine may cause drowsiness and impair ability to perform hazardous activities requiring mental alertness. Use cautiously in breast-feeding women as desloratadine passes into breast milk. RediTabs&reg; contain aspartame which is metabolized to phenylalanine and must be used with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and adjust dosage in patients with liver or renal impairment. Syrup contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F157677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1057745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with food has no effect on desloratadine's bioavailability",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F157679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F157690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies desloratadine as pregnancy category C. The use of antihistamines for the treatment of rhinitis during pregnancy is generally considered to be safe at recommended doses. Information related to the use of desloratadine during pregnancy is limited; therefore, other agents may be preferred. Desloratadine is the primary metabolite of loratadine; refer to the Loratadine monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Improvement in signs and symptoms of allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1057737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic serum levels (not used clinically): Desloratadine: 2.5-4 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-acting tricyclic antihistamine with selective peripheral histamine H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonistic properties; active metabolite of loratadine",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 82% to 87% (desloratadine), 85% to 89% (metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized to an active metabolite (3-hydroxydesloratadine); subset of population are slow metabolizers of desloratadine (7% of patients in clinical trials were slow-metabolizers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 27 hours (both desloratadine and active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 87% eliminated via urine and feces as metabolic products",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/41/44692?source=see_link\">",
"      see \"Desloratadine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink plenty of water; may cause dry mouth; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; avoid alcohol",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Murdoch D, Goa KL, and Keam SJ, &ldquo;Desloratadine: An Update of Its Efficacy in the Management of Allergic Disorders,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2003, 63(19):2051-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23765/abstract-text/12962522/pubmed\" id=\"12962522\" target=\"_blank\">",
"        12962522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13211 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-213.134.24.46-B0B7A2AA67-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23765=[""].join("\n");
var outline_f23_13_23765=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157702\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157703\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057735\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057727\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157682\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157669\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057739\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057731\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057738\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258803\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157737\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057743\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057726\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057725\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837880\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157677\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057745\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157679\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157690\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057734\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057737\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057724\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057741\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057742\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057733\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13211\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13211|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12934?source=related_link\">",
"      Desloratadine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/41/44692?source=related_link\">",
"      Desloratadine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_13_23766="Junctional premature tutorial";
var content_f23_13_23766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Junctional premature complexes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 84px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrioventricular junctional premature beats (beats 2 and 4) are early ectopic beats which originate in or near the AV junction and have a QRS morphology that resembles the sinus complex. Although their timing and morphology are similar to that of an atrial premature beat, there is no P wave present before the QRS complex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23766=[""].join("\n");
var outline_f23_13_23766=null;
var title_f23_13_23767="Filgrastim: Drug information";
var content_f23_13_23767=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Filgrastim: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/22/21861?source=see_link\">",
"    see \"Filgrastim: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/27/44470?source=see_link\">",
"    see \"Filgrastim: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neupogen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neupogen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F171247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Colony Stimulating Factor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F171207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens and institution protocols should also be consulted. Rounding doses to the nearest vial size may enhance patient convenience and reduce costs without compromising clinical response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Chemotherapy-induced neutropenia",
"     </b>",
"     SubQ, I.V.: 5 mcg/kg/day; doses may be increased by 5 mcg/kg (for each chemotherapy cycle) according to the duration and severity of the neutropenia; continue for up to 14 days or until the ANC reaches 10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bone marrow transplantation (in patients with cancer; to shorten the duration of neutropenia and neutropenia-related events):",
"     </b>",
"     SubQ, I.V.: 10 mcg/kg/day (administer &ge;24 hours after chemotherapy and &ge;24 hours after bone marrow infusion); adjust the dose according to the duration and severity of neutropenia; recommended steps based on neutrophil response:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     When ANC &gt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     for 3 consecutive days: Reduce filgrastim dose to 5 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If ANC remains &gt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     for 3 more consecutive days: Discontinue filgrastim",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If ANC decreases to &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume at 5 mcg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If ANC decreases to &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     during the 5 mcg/kg/day dose: Increase filgrastim to 10 mcg/kg/day and follow the above steps.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peripheral blood progenitor cell (PBPC) collection:",
"     </b>",
"     SubQ: 10 mcg/kg daily, usually for 6-7 days. Begin at least 4 days before the first apheresis and continue until the last apheresis; consider dose adjustment for WBC &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe chronic neutropenia:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Congenital:",
"     </i>",
"     Initial: 6 mcg/kg twice daily; adjust the dose based on ANC and clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Idiopathic/cyclic:",
"     </i>",
"     Initial: 5 mcg/kg/day; adjust the dose based on ANC and clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anemia in myelodysplastic syndrome (unlabeled use; in combination with epoetin):",
"     </b>",
"     SubQ: 30 mcg, 75 mcg, or 150 mcg once daily (Hellstrom-Lindberg, 1998)",
"     <b>",
"      or",
"     </b>",
"     1 mcg/kg once daily (Greenberg, 2009)",
"     <b>",
"      or",
"     </b>",
"     75 mcg, 150 mcg or 300 mcg/dose 3 times/week (Hellstrom-Lindberg, 2003)",
"     <b>",
"      or",
"     </b>",
"     1-2 mcg/kg/dose 1-3 times/week (NCCN MDS guidelines v.2.2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hematopoietic stem cell mobilization in autologous transplantation in patients with non-Hodgkin&rsquo;s lymphoma or multiple myeloma (in combination with plerixafor; unlabeled use):",
"     </b>",
"     SubQ: 10 mcg/kg once daily; begin 4 days before initiation of plerixafor; continue G-CSF on each day prior to apheresis for up to 8 days (DiPersio,",
"     <i>",
"      JCO",
"     </i>",
"     2009; DiPersio,",
"     <i>",
"      Blood",
"     </i>",
"     2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hepatitis C treatment-associated neutropenia (unlabeled use):",
"     </b>",
"     SubQ: 150 mcg once weekly to 300 mcg 3 times/week; titrate to maintain ANC between 750-10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (Younossi, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F171227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/27/44470?source=see_link\">",
"      see \"Filgrastim: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Details concerning dosing in combination regimens and institution protocols should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chemotherapy induced neutropenia, bone marrow transplantation, peripheral blood progenitor cell collection, severe chronic neutropenia:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Neutropenia (ANC &lt;500/mm",
"      <sup>",
"       3",
"      </sup>",
"      ) due to zidovudine treatment for HIV-infection (unlabeled use):",
"     </b>",
"     SubQ, I.V.: 5-10 mcg/kg once daily (AIDS",
"     <i>",
"      info",
"     </i>",
"     guidelines, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F171208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neupogen&reg;: 300 mcg/mL (1 mL, 1.6 mL) [contains polysorbate 80, sodium 0.035 mg/mL, sorbitol; vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neupogen&reg;: 600 mcg/mL (0.5 mL, 0.8 mL) [contains natural rubber/natural latex in packaging, polysorbate 80, sodium 0.035 mg/mL, sorbitol; prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F14944583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tbo-filgrastim: FDA approved August 2012; availability anticipated November 2013.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tbo-filgrastim is a short-acting recombinant form of G-CSF (biologically similar to Neupogen&reg;), indicated to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F171183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered by SubQ injection, either as a bolus injection (chemotherapy-induced neutropenia) or as a continuous infusion (chemotherapy-induced neutropenia, bone marrow transplantation, and peripheral blood progenitor cell collection). May also be administered I.V. as a short infusion over 15-30 minutes (chemotherapy-induced neutropenia) or by continuous infusion (chemotherapy-induced neutropenia) or as a 4- or 24-hour infusion (bone marrow transplantation). Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F171254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      incompatible",
"     </b>",
"     with NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cefazolin, cefotetan, ceftazidime, chlorpromazine, cimetidine, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin HCl, dexamethasone sodium phosphate, diphenhydramine, doxorubicin HCl, doxycycline, droperidol, enalaprilat, famotidine, floxuridine, fluconazole, fludarabine, gallium nitrate, ganciclovir, granisetron, haloperidol lactate, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, idarubicin, ifosfamide, leucovorin calcium, lorazepam, mechlorethamine, melphalan, meperidine, mesna, methotrexate, metoclopramide, minocycline, mitoxantrone, morphine, nalbuphine, ondansetron, potassium chloride, promethazine, ranitidine, sodium bicarbonate, streptozocin, sulfamethoxazole/trimethoprim, ticarcillin/clavulanate, tobramycin, vancomycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, cefepime, cefotaxime, cefoxitin, ceftriaxone, cefuroxime, clindamycin, etoposide, fluorouracil, furosemide, heparin, mannitol, methylprednisolone sodium succinate, metronidazole, mitomycin, piperacillin, prochlorperazine edisylate, thiotepa.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dactinomycin, gentamicin, imipenem/cilastatin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F171182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cancer patients (nonmyeloid malignancies) receiving myelosuppressive chemotherapy",
"     </b>",
"     to decrease the incidence of infection (febrile neutropenia) in regimens associated with a high incidence of neutropenia with fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute myelogenous leukemia (AML)",
"     </b>",
"     following induction or consolidation chemotherapy to shorten time to neutrophil recovery and reduce the duration of fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cancer patients (nonmyeloid malignancies) receiving bone marrow transplant",
"     </b>",
"     to shorten the duration of neutropenia and neutropenia-related events (eg, neutropenic fever)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Peripheral stem cell transplantation",
"     </b>",
"     to mobilize hematopoietic progenitor cells for apheresis collection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Severe chronic neutropenia (SCN; chronic administration)",
"     </b>",
"     to reduce the incidence and duration of neutropenic complications (fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital, cyclic, or idiopathic neutropenia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4040409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of anemia in myelodysplastic syndrome (in combination with epoetin); mobilization of hematopoietic stem cells (HSC) for collection and subsequent autologous transplantation (in combination with plerixafor) in patients with non-Hodgkin&rsquo;s lymphoma (NHL) and multiple myeloma (MM); treatment of neutropenia in HIV-infected patients receiving zidovudine; hepatitis C treatment-associated neutropenia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Neupogen&reg; may be confused with Epogen&reg;, Neulasta&reg;, Neumega&reg;, Nutramigen&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Neupogen [U.S., Canada, and multiple international markets] may be confused with Neupro brand name for rotigotine [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F171245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Petechiae (&le;17%), rash (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: LDH increased, uric acid increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Splenomegaly (severe chronic neutropenia: 30%; rare in other patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone/skeletal pain (22% to 33%; dose related), commonly in the lower back, posterior iliac crest, and sternum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Epistaxis (9% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hyper-/hypotension (4%), myocardial infarction/arrhythmias (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (10%), vomiting (7%), peritonitis (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukocytosis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Transfusion reaction (&le;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute respiratory distress syndrome (ARDS), allergic reactions, alopecia, alveolar hemorrhage, arthralgia, bone density decreased, capillary leak syndrome, cerebral hemorrhage, cutaneous vasculitis, dyspnea, edema (facial), erythema nodosum, hematuria, hemoptysis, hepatomegaly, hypersensitivity reaction, injection site reaction, osteoporosis, pericarditis, proteinuria, psoriasis exacerbation, pulmonary infiltrates, renal insufficiency, sickle cell crisis, splenic rupture, Sweet&rsquo;s syndrome (acute febrile dermatosis), tachycardia, thrombocytopenia (in PBPC mobilization), thrombophlebitis, transient supraventricular arrhythmia, urticaria, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F171186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to filgrastim,",
"     <i>",
"      E. coli",
"     </i>",
"     -derived proteins, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F171168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse reactions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Rash, urticaria, facial edema, wheezing, dyspnea, tachycardia, and/or hypotension have occurred with first or subsequent doses. Reactions tended to involve &ge;2 body systems and occur more frequently with intravenous administration and generally within 30 minutes of administration. Symptoms recurred in &gt;50% of patients when rechallenged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alveolar hemorrhage: Reports of alveolar hemorrhage, manifested as pulmonary infiltrates and hemoptysis, have occurred in healthy donors undergoing PBPC collection (not FDA approved for use in healthy donors); hemoptysis resolved upon discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cutaneous vasculitis: Has been reported, generally occurring in SCN patients on long-term therapy; symptoms generally developed with increasing absolute neutrophil count (ANC) and subsided when the ANC decreased; dose reductions may improve symptoms to allow for continued therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory distress syndrome: Rare cases of acute respiratory distress syndrome (ARDS) have been reported (possibly due to influx of neutrophils to sites of lung inflammation); withhold or discontinue filgrastim if ARDS occurs; patients must be instructed to report respiratory distress; monitor for fever, infiltrates, or respiratory distress.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Splenic rupture: Rare cases of splenic rupture have been reported (may be fatal); patients must be instructed to report left upper quadrant pain or shoulder tip pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell disorders: May precipitate severe sickle cell crises, sometimes resulting in fatalities, in patients with sickle cell disorders; carefully evaluate potential risks and benefits.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cytotoxic chemotherapy: Do not use filgrastim in the period 24 hours before to 24 hours after administration of cytotoxic chemotherapy because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Plerixafor: Increases circulating leukocytes when used in conjunction with plerixafor for stem cell mobilization; monitor WBC; use with caution in patients with neutrophil count &gt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . May also release tumor cells from marrow which could be collected in leukapheresis product; potential effect of tumor cell reinfusion is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myelosuppressive chemotherapy recipients: Safety and efficacy have not been established with patients receiving chemotherapy associated with delayed myelosuppression (eg, nitrosoureas, mitomycin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation therapy recipients: Avoid concurrent radiation therapy with filgrastim; safety and efficacy have not been established with patients receiving radiation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Severe congenital neutropenia (SCN): Filgrastim use prior to appropriate diagnosis of SCN may impair proper evaluation and treatment for neutropenia not due to SCN. Cytogenetic abnormalities, transformation to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been observed in patients treated with filgrastim for congenital neutropenia; a longer duration of treatment and poorer ANC response appear to increase the risk. Carefully consider the risk of continuing filgrastim in patients who develop abnormal cytogenetics or MDS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: The packaging of some dosage forms may contain latex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Other warnings/precautions:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor growth factor: May potentially act as a growth factor for any tumor type; caution should be exercised when using in any malignancy with myeloid characteristics.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bleomycin: Filgrastim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: Filgrastim may enhance the adverse/toxic effect of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2734401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated adverse effects and fetal loss. Filgrastim has been shown to cross the placenta in humans. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit to mother justifies risk to the fetus. Women who become pregnant during filgrastim treatment are encouraged to enroll in Amgen&rsquo;s Pregnancy Surveillance Program (1-800-772-6436).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F171215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F171190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F171189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Neupogen Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mcg/0.5 mL (0.5 mL): $361.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mcg/mL (1 mL): $329.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     480 mcg/0.8 mL (0.8 mL): $576.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     480 mcg/1.6 mL (1.6 mL): $524.94",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F171177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets prior to treatment and twice weekly during filgrastim treatment for chemotherapy-induced neutropenia (3 times/week following marrow transplantation). For severe chronic neutropenia, monitor CBC with differential and platelets twice weekly during the first month of therapy and for 2 weeks following dose adjustments; once clinically stable, monthly for 1 year and quarterly thereafter; for congenital neutropenia also monitor bone marrow and karyotype prior to treatment; and monitor marrow and cytogenetics annually throughout treatment. Monitor temperature.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F171180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No additional clinical benefit seen when filgrastim is used with ANC &gt;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F171191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Biocilin (MX);",
"     </li>",
"     <li>",
"      Biofigran (CO);",
"     </li>",
"     <li>",
"      Biofilgran (MX);",
"     </li>",
"     <li>",
"      Endufil (PH);",
"     </li>",
"     <li>",
"      Filatil (CR, DO, GT, HN, MX, NI, PA, SV);",
"     </li>",
"     <li>",
"      Filgen (EC, TH);",
"     </li>",
"     <li>",
"      Gran (JP, MY, SG, TH);",
"     </li>",
"     <li>",
"      Granulokine (BR);",
"     </li>",
"     <li>",
"      Grimatin (JP);",
"     </li>",
"     <li>",
"      Inmunef (MX);",
"     </li>",
"     <li>",
"      Jiexin (CL);",
"     </li>",
"     <li>",
"      Leucogen (ID);",
"     </li>",
"     <li>",
"      Leucostim (KP);",
"     </li>",
"     <li>",
"      Macroleuco (PH);",
"     </li>",
"     <li>",
"      Neukine (TH);",
"     </li>",
"     <li>",
"      Neupogen (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, HU, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, NZ, OM, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SE, SK, SL, SN, SR, SY, TH, TN, TR, TT, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Neutromax (PE);",
"     </li>",
"     <li>",
"      Nivestim (AU, GB, HK);",
"     </li>",
"     <li>",
"      Recombicyte (PH);",
"     </li>",
"     <li>",
"      SciLocyte (PH);",
"     </li>",
"     <li>",
"      Tevagastrim (IL);",
"     </li>",
"     <li>",
"      White-C (PH);",
"     </li>",
"     <li>",
"      Zarzio (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F171167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates the production, maturation, and activation of neutrophils; filgrastim activates neutrophils to increase both their migration and cytotoxicity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F171185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~24 hours; plateaus in 3-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Neutrophil counts generally return to baseline within 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: SubQ: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 150 mL/kg; no evidence of drug accumulation over a 11- to 20-day period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Systemically degraded",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.8-3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: SubQ: 2-8 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Calandra G, McCarty J, McGuirk J, et al, &ldquo;AMD3100 Plus G-CSF Can Successfully Mobilize CD34+ Cells From Non-Hodgkin's Lymphoma, Hodgkin's Disease and Multiple Myeloma Patients Previously Failing Mobilization With Chemotherapy and/or Cytokine Treatment: Compassionate Use Data,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2008, 41(4):331-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/17994119/pubmed\" id=\"17994119\" target=\"_blank\">",
"        17994119",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DiPersio JF, Micallef I, Stiff PJ, et al, &ldquo;Phase III Prospective Randomized Double-Blinded Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin&rsquo;s Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(28):4767-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/19720922/pubmed\" id=\"19720922\" target=\"_blank\">",
"        19720922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DiPersio JF, Stadtmauer EA, Nadamanee NP, et al, &ldquo;Plerixafor and G-CSF Versus Placebo and G-CSF to Moboilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients With Multiple Myeloma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 113(23):5720-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/19363221/pubmed\" id=\"19363221\" target=\"_blank\">",
"        19363221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Strader DB, Thomas DL, et al, &ldquo;Diagnosis, Management and Treatment of Hepatitis C: An Update,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(4):1335-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/19330875/pubmed\" id=\"19330875\" target=\"_blank\">",
"        19330875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenberg PL, Sun Z, Miller KB, et al, &ldquo;Treatment of Myelodysplastic Syndrome Patients With Erythropoietin With or Without Granulocyte Colony-Stimulating Factor: Results of a Prospective Randomized Phase 3 Trial by the Eastern Cooperative Oncology Group (E1996),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2009, 114(12):2393-400.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/19564636/pubmed\" id=\"19564636\" target=\"_blank\">",
"        19564636",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, Panel on Clinical Practices for Treatment of HIV Infection,&rdquo; January 10, 2011. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hellstr&ouml;m-Lindberg E, Ahlgren T, Beguin Y, et al, &ldquo;Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results from a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1998, 92(1):68-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/9639501/pubmed\" id=\"9639501\" target=\"_blank\">",
"        9639501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hellstr&ouml;m-Lindberg E, Gulbrandsen N, Lindberg G, et al, &ldquo;A Validated Decision Model for Treating the Anaemia of Myelodysplastic Syndromes With Erythropoietin + Granulocyte Colony-Stimulating Factor: Significant Effects on Quality of Life,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2003, 120(6):1037-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/12648074/pubmed\" id=\"12648074\" target=\"_blank\">",
"        12648074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson PA, West NJ, Spadoni V, et al, &ldquo;Sterility of Filgrastim (G-CSF) in Syringes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(11):1238-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/913403/pubmed\" id=\"913403\" target=\"_blank\">",
"        913403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      J&auml;dersten M, Montgomery SM, Dybedal I, et al, &ldquo;Long-Term Outcome of Treatment of Anemia in MDS with Erythropoietin and G-CSF,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 106(3):803-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/15840690/pubmed\" id=\"15840690\" target=\"_blank\">",
"        15840690",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuwabara T, Kobayashi S, and Sugiyama Y, &ldquo;Pharmacokinetics and Pharmacodynamics of a Recombinant Human Granulocyte Colony-Stimulating Factor,&rdquo;",
"      <i>",
"       Drug Metab Rev",
"      </i>",
"      , 1996, 28(4):625-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/8959393/pubmed\" id=\"8959393\" target=\"_blank\">",
"        8959393",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin WG, Ristow KM, Habermann TM, et al, &ldquo;Bleomycin Pulmonary Toxicity has a Negative Impact on the Outcome of Patients With Hodgkin&rsquo;s Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7614-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/16186594/pubmed\" id=\"16186594\" target=\"_blank\">",
"        16186594",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCullough JM, Sprentall-Nankervis E, Potcova CA, et al, &ldquo;Recovery and Biological activity of Filgrastim After Injection Through Silicone Rubber Catheters,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(2):186-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/12879546/pubmed\" id=\"12879546\" target=\"_blank\">",
"        12879546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Myelodysplastic Syndromes,&rdquo; Version 2.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/mds.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Myeloid Growth Factors,&rdquo; Version 1.2011. Available at  file://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nemunaitis J, &ldquo;A Comparative Review of Colony-Stimulating Factors,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1997, 54(5):709-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/9360058/pubmed\" id=\"9360058\" target=\"_blank\">",
"        9360058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenberg PS, Alter BP, Bolyard AA, et al, &ldquo;The Incidence of Leukemia and Mortality From Sepsis in Patients With Severe Congenital Neutropenia Receiving Long-Term G-CSF Therapy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(12): 4628-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/16497969/pubmed\" id=\"16497969\" target=\"_blank\">",
"        16497969",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schaison G, Eden OB, Henze G, et al, &ldquo;Recommendations on the Use of Colony-Stimulating Factors in Children: Conclusions of a European Panel,&rdquo;",
"      <i>",
"       E J Pediatr",
"      </i>",
"      , 1998, 157(12):955-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/9877032/pubmed\" id=\"9877032\" target=\"_blank\">",
"        9877032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh RF, Corelli RL, and Guglielmo BJ, &ldquo;Sterility of Unit Dose Syringes of Filgrastim and Sargramostim,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1994, 51(15):2811-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/7531941/pubmed\" id=\"7531941\" target=\"_blank\">",
"        7531941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al, &ldquo;2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(19):3187-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/16682719/pubmed\" id=\"16682719\" target=\"_blank\">",
"        16682719",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Younossi ZM, Nader FH, Bai C, et al, &ldquo;A Phase II Dose Finding Study of Darbepoetin Alpha and Filgrastim for the Management of Anaemia and Neutropenia in Chronic Hepatitis C Ttreatment,&rdquo;",
"      <i>",
"       J Viral Hepat",
"      </i>",
"      , 2008, 15(5):370-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23767/abstract-text/18194172/pubmed\" id=\"18194172\" target=\"_blank\">",
"        18194172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8446 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23767=[""].join("\n");
var outline_f23_13_23767=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171203\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171204\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171247\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171207\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171227\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171208\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881429\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881430\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171179\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171164\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944583\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171183\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171254\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171182\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4040409\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171257\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171245\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171186\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171168\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299335\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220395\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171175\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2734401\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171215\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171190\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171189\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171177\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171180\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171191\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171167\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171185\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8446\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8446|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/22/21861?source=related_link\">",
"      Filgrastim: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/27/44470?source=related_link\">",
"      Filgrastim: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_13_23768="Levofloxacin (systemic): Pediatric drug information";
var content_f23_13_23768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levofloxacin (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/8/16521?source=see_link\">",
"    see \"Levofloxacin (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/32/13830?source=see_link\">",
"    see \"Levofloxacin (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8398365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8398376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levaquin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8398377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      APO-Levofloxacin;",
"     </li>",
"     <li>",
"      AVA-Levofloxacin;",
"     </li>",
"     <li>",
"      CO Levofloxacin;",
"     </li>",
"     <li>",
"      Levaquin&reg;;",
"     </li>",
"     <li>",
"      Mylan-Levofloxacin;",
"     </li>",
"     <li>",
"      Novo-Levofloxacin;",
"     </li>",
"     <li>",
"      PMS-Levofloxacin;",
"     </li>",
"     <li>",
"      Sandoz-Levofloxacin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10501846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10501924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/8/16521?source=see_link\">",
"      see \"Levofloxacin (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing, susceptible infection",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012):",
"     <b>",
"      Note:",
"     </b>",
"     Use in pediatric patients should be reserved for severe infection; use for mild or moderate infection is inappropriate. Safety for duration of therapy longer than 14 days or for infants younger than 6 months of age has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Severe infection:  Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &lt;5 years: 10 mg/kg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &ge;5 years: 10 mg/kg/dose once daily; maximum dose 500 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anthrax, postexposure (inhalation):",
"     </b>",
"     Infants &ge;6 months, Children, and Adolescents: Oral, I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Begin as soon as possible after exposure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;50 kg: 8 mg/kg/dose every 12 hours for 60 days; maximum dose: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;50 kg: 500 mg every 24 hours for 60 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Plague",
"      <i>",
"       (Yersinia pestis)",
"      </i>",
"      , prophylaxis or treatment:",
"     </b>",
"     Infants &ge;6 months, Children, and Adolescents: Oral, I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Begin as soon as possible after exposure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;50 kg: 8 mg/kg/dose every 12 hours for 10-14 days; maximum dose: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;50 kg: 500 mg every 24 hours for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pneumonia, community-acquired (CAP)",
"     </b>",
"     (IDSA/PIDS, 2011):",
"     <b>",
"      Note:",
"     </b>",
"     May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected. In children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Typical pathogens:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Haemophilus influenza:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Mild infection/step down therapy: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Infants &ge;6 months and Children &lt;5 years: 8-10 mg/kg/dose every 12 hours; maximum daily dose: 750 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Children &ge;5 years and Adolescents &le;16 years: 8-10 mg/kg/dose once every 24 hours; maximum daily dose: 750 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Severe infections: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Infants &ge;6 months and Children &lt;5 years: 8-10 mg/kg/dose every 12 hours; maximum daily dose: 750 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Children &ge;5 years and Adolescents &le;16 years: 8-10 mg/kg/dose once every 24 hours; maximum daily dose: 750 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Streptococcus pneumonia:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Penicillin-sensitive: Mild infection/step down therapy: Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Levofloxacin is not recommended for routine use for the treatment of mild to moderate infection (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Infants &ge;6 months and Children &lt;5 years: 8-10 mg/kg/dose every 12 hours; maximum daily dose: 750 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Children &ge;5 years and Adolescents &le;16 years: 8-10 mg/kg/dose once every 24 hours; maximum daily dose: 750 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Penicillin-resistant:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Infants &ge;6 months and Children &lt;5 years: 8-10 mg/kg/dose every 12 hours; maximum daily dose: 750 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Children &ge;5 years and Adolescents &le;16 years: 8-10 mg/kg/dose once every 24 hours; maximum daily dose: 750 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;\">",
"     Severe infections: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:16em;\">",
"     Infants &ge;6 months and Children &lt;5 years: 8-10 mg/kg/dose every 12 hours; maximum daily dose: 750 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:16em;\">",
"     Children &ge;5 years and Adolescents &le;16 years: 8-10 mg/kg/dose once every 24 hours; maximum daily dose: 750 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Atypical pathogens (",
"     <i>",
"      Mycoplasma pneumonia",
"     </i>",
"     or",
"     <i>",
"      Chlamydia ssp",
"     </i>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild infection/step-down therapy: Oral: Adolescents with skeletal maturity: 500 mg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Severe infections: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Infants &ge;6 months and Children &lt;5 years: 8-10 mg/kg/dose every 12 hours; maximum daily dose: 750 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children &ge;5 years and Adolescents &le;16 years: 8-10 mg/kg/dose once every 24 hours; maximum daily dose: 750 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Rhinosinusitis, acute bacterial: Note:",
"     </b>",
"     Recommended in the following types of patients: Type I penicillin allergy, after failure of initial therapy or in patients at risk for antibiotic resistance (eg, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month) (Chow, 2012). Children and Adolescents: Oral, I.V.: 10-20 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 12-24 hours for 10-14 days; maximum daily dose: 500 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anthrax, postexposure (inhalation):",
"     </b>",
"     Oral, I.V.: 500 mg every 24 hours for 60 days beginning as soon as possible after exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Bronchitis, chronic:",
"     </b>",
"     Oral, I.V.: 500 mg every 24 hours for at least 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Plague",
"      <i>",
"       (Yersinia pestis)",
"      </i>",
"      , prophylaxis or treatment:",
"     </b>",
"     Oral, I.V.: 500 mg every 24 hours for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pneumonia:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Community-acquired: 500 mg every 24 hours for 7-14 days or 750 mg every 24 hours for 5 days (efficacy of 5-day regimen for MDRSP not established)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Nosocomial: 750 mg every 24 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prostatitis, chronic bacterial:",
"     </b>",
"     Oral, I.V.: 500 mg every 24 hours for 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Rhinosinusitis, acute bacterial:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer&rsquo;s recommendations: 500 mg every 24 hours for 10-14 days or 750 mg every 24 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate recommendations: 500 mg every 24 hours for 5-7 days (Chow, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Skin and skin structure infections:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Complicated: 750 mg every 24 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Uncomplicated: 500 mg every 24 hours for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Urinary tract infection (UTI):",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Complicated or acute pyelonephritis: 250 mg every 24 hours for 10 days or 750 mg every 24 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Uncomplicated: 250 mg every 24 hours for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: The following adjustments have been recommended (Aronoff, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     Renally adjusted dose recommendations are based on doses of 5-10 mg/kg/dose every 12 hours for children &le;5 years and 5-10 mg/kg/dose every 24 hours for children &gt;5 years.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR &ge;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR 10-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 5-10 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 5-10 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intermittent hemodialysis: 5-10 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Peritoneal dialysis (PD): 5-10 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous renal replacement therapy (CRRT): 10 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Normal renal function dosing of 750 mg/day:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-49 mL/minute: Administer 750 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-19 mL/minute: Administer 750 mg initial dose, followed by 500 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hemodialysis (administer after hemodialysis on dialysis days)/peritoneal dialysis (PD): Administer 750 mg initial dose, followed by 500 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Normal renal function dosing of 500 mg/day:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-49 mL/minute: Administer 500 mg initial dose, followed by 250 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-19 mL/minute: Administer 500 mg initial dose, followed by 250 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hemodialysis (administer after hemodialysis on dialysis days)/peritoneal dialysis (PD): Administer 500 mg initial dose, followed by 250 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Normal renal function dosing of 250 mg/day:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-49 mL/minute: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-19 mL/minute: Administer 250 mg every 48 hours (except in uncomplicated UTI, where no dosage adjustment is required)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hemodialysis (administer after hemodialysis on dialysis days)/peritoneal dialysis (PD): No information available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CVVH: Loading dose of 500-750 mg followed by 250 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CVVHD: Loading dose of 500-750 mg followed by 250-500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CVVHDF: Loading dose of 500-750 mg followed by 250-750 mg every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8408135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W [preservative free]: 250 mg (50 mL); 500 mg (100 mL); 750 mg (150 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levaquin&reg;: 250 mg (50 mL); 500 mg (100 mL); 750 mg (150 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 25 mg/mL (20 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 25 mg/mL (100 mL, 200 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levaquin&reg;: 25 mg/mL (480 mL) [contains benzyl alcohol, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg, 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levaquin&reg;: 250 mg, 500 mg, 750 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8398378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8398367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088619.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088619.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10501964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Tablets may be administered with or without food; oral solution should be administered 1 hour before or 2 hours after eating; avoid antacid use within 2 hours of administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: If preparing from vials, further dilute dose at a concentration not to exceed 5 mg/mL. Administer by slow I.V. infusion over 60-90 minutes (250-500 mg over 60 minutes; 750 mg over 90 minutes); avoid rapid or bolus I.V. infusion due to risk of hypotension; not for I.M., SubQ, or intrathecal administration",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8404709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS with 20 mEq/L KCl, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, Plasma-Lyte&reg; 56 in 5% dextrose, sodium lactate (M/6);",
"     <b>",
"      incompatible",
"     </b>",
"     with mannitol 20%, sodium bicarbonate 5%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, aminophylline, ampicillin, anidulafungin, bivalirudin, caffeine citrate, cefotaxime, cimetidine, clindamycin, daptomycin, dexamethasone sodium phosphate, dexmedetomidine, dobutamine, dopamine, doripenem, epinephrine, fenoldopam, fentanyl, gentamicin, hetastarch in lactated electrolyte injection (Hextend&reg;), hydromorphone, isoproterenol, lidocaine, linezolid, lorazepam, magnesium sulfate, metoclopramide, metronidazole, morphine, octreotide, oxacillin, pancuronium, penicillin G sodium, phenobarbital, phenylephrine, potassium chloride, sodium bicarbonate, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, alprostadil, azithromycin, furosemide, heparin, indomethacin, nitroglycerin, nitroprusside, pantoprazole, propofol, telavancin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Caspofungin, insulin (regular).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Heparin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10501910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Solution: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablets: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Vial: Store at room temperature; protect from light; solutions further diluted to 5 mg/mL in appropriate fluid are stable: Room temperature: 72 hours; refrigeration: 14 days; and frozen at -20&deg;C (-4&deg;F): 6 months. If frozen, do not thaw in microwave or by bath immersion; do not refreeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premixed: Store at &le;25&deg;C (77&deg;F); do not freeze. Brief exposure to 40&deg;C (104&deg;F) does not affect product. Protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10501903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of plague and postexposure prevention of inhalational anthrax (FDA approved for ages &ge;6 months and adults); treatment of acute bacterial sinusitis, pneumonia (nosocomial and community-acquired), acute bacterial exacerbation of chronic bronchitis, skin and skin structure infections (uncomplicated or complicated), chronic bacterial prostatitis, urinary tract infections (uncomplicated or complicated), and acute pyelonephritis due to multidrug-resistant organisms susceptible to levofloxacin (FDA approved in ages &ge;18 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8398366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levaquin&reg; may be confused with Levoxyl&reg;, Levsin/SL&reg;, Lovenox&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levofloxacin may be confused with levETIRAcetam, levodopa, Levophed&reg;, levothyroxine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8401456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Moniliasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal taste, acute renal failure, agitation, agranulocytosis, alkaline phosphatase increased, altered sense of smell, allergic reaction (including anaphylaxis, angioedema,  rash, pneumonitis, and serum sickness); anaphylactoid reaction, anemia (including aplastic and hemolytic) anorexia, anxiety, arrhythmia (including ventricular tachycardia/fibrillation and torsade de pointes), arthralgia, bronchospasm, cardiac arrest,",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD), confusion, depression, dysphonia, EEG abnormalities, encephalopathy (rare), eosinophilia, epistaxis, erythema multiforme, esophagitis, fever, gait abnormal, gastritis (including gastroenteritis), glossitis, granulocytopenia, hallucination, hepatic failure (some fatal), hepatic function abnormal, hepatitis, hyper-/hypoglycemia, hyperkalemia, hyperkinesias, hyper-/hypotension, hypertonia, hypoacusis, INR increased, intestinal obstruction, intracranial pressure increased, involuntary muscle contractions, jaundice, leukocytosis, leukopenia, leukorrhea, loss of taste perception, lymphadenopathy, multiple organ failure, muscle injury, myalgia, myasthenia gravis exacerbation, nephritis (interstitial), palpitation, pancreatitis, pancytopenia, paralysis, paranoia, paresthesia, peripheral neuropathy, phlebitis,photosensitivity/phototoxicity, pneumonitis, prothrombin time increased, pseudotumor cerebri, psychosis, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, renal function abnormal, rhabdomyolysis, seizure, skeletal pain, skin disorder, sleep disorders (including abnormal dreams and nightmares) somnolence, Stevens-Johnson syndrome, stomatitis, suicide attempt/ideation, syncope, tachycardia, tendonitis, tendon rupture, tinnitus, toxic epidermal necrolysis, transaminases increased, thrombocytopenia, tremor, urticaria, vasculitis (leukocytoclastic), vasodilatation, vertigo, visual disturbances",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10501904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levofloxacin, any component, or other quinolones",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10501907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage adjustment required. Rarely, crystalluria has occurred; urine alkalinity may increase the risk; ensure adequate hydration during therapy. Use with caution in patients with  G6PD deficiency; hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency. Use with caution in individuals at risk of seizures (CNS disorders or severe cerebral arteriosclerosis), or concurrent therapy with medications which may lower seizure threshold; potential for seizures with use exists, although very rare; may be increased with concomitant NSAID therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fluoroquinolones may prolong QT",
"     <sub>",
"      C",
"     </sub>",
"     interval and  rare cases of torsade de pointes have been reported in patients taking levofloxacin;  avoid use  in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, uncorrected hypokalemia or hypomagnesemia, on concurrent therapy with Class Ia or Class III antiarrhythmics or other medications known to prolong the QT interval (cisapride, erythromycin, antipsychotics, and tricyclic antidepressants), or in patients with bradycardia, cardiomyopathy, or recent myocardial ischemia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause alterations in glucose regulation; fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia; most often reported in elderly patients with diabetes, but has also been reported in patients without a prior history of diabetes; prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect; was most evident with gatifloxacin (no longer marketed as systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May rarely cause moderate to severe phototoxicity reactions; avoid excessive sunlight and take precautions to limit exposure (eg, loose-fitting clothing, sunscreen);  discontinue use if phototoxicity occurs.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10501905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tendonitis and tendon rupture have been reported with fluoroquinolones in patients of all ages",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; increased risk in patients taking concomitant corticosteroids; with rheumatoid arthritis; age &gt;60 years; and with kidney, heart, or lung transplants; usually involves the Achilles, hand, or shoulder tendons and can occur during therapy or up to a few months after therapy completion. Musculoskeletal disorders have been observed more frequently in pediatric patients treated with levofloxacin than controls; increased osteochondrosis in immature rats and dogs was observed with levofloxacin and fluoroquinolones have caused arthropathy with erosions of the cartilage in weight-bearing joints of immature animals. Safety of use in pediatric patients for &gt;14 days of therapy has not been studied. Fluoroquinolones, including levofloxacin, may exacerbate muscle weakness associated with myasthenia gravis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; cases of severe exacerbations, including the need for ventilatory support and deaths, have been reported; avoid use in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Toxic psychoses, tremor, restlessness, anxiety, lightheadedness, paranoia, depression, nightmares, insomnia, confusion, and very rarely hallucinations, increased intracranial pressure (including pseudotumor cerebri), or seizures may occur; use with caution in patients with known or suspected CNS disorder; discontinue in patients who experience significant CNS adverse effects (eg, dizziness, hallucinations, seizures, suicidal ideations or actions). Rare cases of polyneuropathy affecting small and/or large axons, resulting in paresthesias, hypoesthesias, dysesthesias, and weakness, have been reported in patients receiving levofloxacin. Discontinue levofloxacin if patient experiences pain, burning, tingling, numbness, or weakness or is found to have deficits in light touch, pain, temperature, position sense, vibrating sensation, or motor strength.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Serious and occasionally fatal hypersensitivity and/or anaphylactic reactions have been reported often following the first dose. Hypersensitivity reactions have been accompanied by cardiovascular collapse, hypotension/shock, seizure, loss of consciousness, tingling, angioedema, airway obstruction, dyspnea, urticaria, itching, and skin reactions. If these reactions occur, discontinue levofloxacin. Resuscitation equipment, oxygen, epinephrine, antihistamine, and a corticosteroid should be readily available to treat hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Idiosyncratic reactions, including toxic epidermal necrolysis, vasculitis, pneumonitis, nephritis, hepatic failure, and/or cytopenias, have usually occurred after multiple doses. Discontinue drug if these reactions occur. Unrelated to hypersensitivity, severe hepatotoxicity (including acute hepatitis and fatalities) has been reported; discontinue therapy immediately if signs and symptoms of hepatitis occur. Prolonged use may result in superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea and pseudomembranous colitis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral solution contains benzyl alcohol and propylene glycol which may be toxic to newborns in high doses; benzyl alcohol may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\").",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8401459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Quinolone Antibiotics may enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the serum concentration of Quinolone Antibiotics. Quinolone Antibiotics may decrease the serum concentration of Didanosine. Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolone antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolone Antibiotics. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Quinolone Antibiotics may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Quinolone Antibiotics. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the absorption of Quinolone Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Quinolone Antibiotics. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Quinolone Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Quinolone Antibiotics may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Quinolone Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10501909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron and mineral supplements decrease levofloxacin concentrations. Food prolongs the time to peak by approximately 1 hour and decreases the peak concentration by 14% (tablet) or 25% (oral solution).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8400751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8400752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies levofloxacin as pregnancy category C. Levofloxacin crosses the placenta. Quinolone exposure during human pregnancy has been reported with other agents (see  Ciprofloxacin [Systemic], Ofloxacin [Systemic], and Norfloxacin [Systemic] monographs). To date, no specific teratogenic effect or increased pregnancy risk has been identified; however, because of concerns of cartilage damage in immature animals exposed to quinolones and the limited levofloxacin specific data, levofloxacin should only be used during pregnancy if a safer option is not available.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10501965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient receiving concurrent levofloxacin and theophylline should have serum levels of theophylline monitored; monitor INR in patients receiving warfarin; monitor blood glucose in patients receiving antidiabetic agents or patients with a history of diabetes; monitor renal, hepatic, and hematopoietic function periodically; number and type of stools/day for diarrhea; hydration status",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10501911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     L-isomer of the racemate, ofloxacin, levofloxacin inhibits DNA gyrase (bacterial topoisomerase II), thereby inhibiting relaxation of supercoiled DNA and promoting breakage of DNA strands. DNA gyrase maintains the superhelical structure of DNA and is required for DNA replication, transcription, repair, recombination, and transposition.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10501912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Well-absorbed; levofloxacin oral tablet and solution formulations are bioequivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Widely distributed in the body, including blister fluid, skin tissue, macrophages, prostate, and lung tissue; excreted in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 1.25 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 24% to 38%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Oral: Within 1-2 hours; food prolongs the time to peak by approximately 1 hour and decreases the peak concentration by 14% (tablet) or 25% (oral solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: 87% excreted unchanged in urine over 48 hours by tubular secretion and glomerular filtration; 4% in feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &lt;5 years: 0.32 &plusmn; 0.08 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 5-10 years: 0.25 &plusmn; 0.05 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 10-12 years: 0.19 &plusmn; 0.05 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 12-16 years: 0.18 &plusmn; 0.03 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 0.15 &plusmn; 0.02 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Not removed by hemodialysis or peritoneal dialysis; supplemental levofloxacin doses are not required",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10501967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/32/13830?source=see_link\">",
"      see \"Levofloxacin (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink plenty of fluids; may cause dizziness or lightheadedness and impair ability to perform activities requiring mental alertness or physical coordination. Notify physician if tendon pain or swelling occurs; palpitations, chest pain, loss of consciousness, signs of allergy, burning, tingling, numbness, or weakness develops; difficulty breathing; or if persistent diarrhea occurs. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11432885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral solution is available (25 mg/mL)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 50 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Ora-Plus&reg; and strawberry syrup NF. Crush six 500 mg levofloxacin tablets in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     60 mL; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label \"shake well\". Stable for 57 days when stored in amber plastic prescription bottles at room temperature or refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     VandenBussche HL, Johnson CE, and Fontana EM, et al, \"Stability of Levofloxacin in an Extemporaneously Compounded Oral Liquid,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1999, 56(22):2316-8.",
"     <span class=\"pubmed-id\">",
"      10582824",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23768/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chien S, Wells TG, Blumer JL, et al, &ldquo;Levofloxacin Pharmacokinetics in Children,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2005, 45(2):153-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23768/abstract-text/15647407 /pubmed\" id=\"15647407 \" target=\"_blank\">",
"        15647407",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, \"IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23768/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ernst ME, Ernst EJ, and Klepser ME, &ldquo;Levofloxacin and Trovafloxacin: The Next Generation of Fluoroquinolones?&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(22):2569-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23768/abstract-text/9397218/pubmed\" id=\"9397218\" target=\"_blank\">",
"        9397218",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller DE, Flume PA, Staab D, et al, \"Levofloxacin Inhalation Solution (MP-376) in Patients With Cystic Fibrosis With",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"      ,\"",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2011, 183(11):1510-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23768/abstract-text/21471106/pubmed\" id=\"21471106\" target=\"_blank\">",
"        21471106",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller DE, Flume PA, Griffith DC, et al, \"Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2011a, 55(6):2636-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23768/abstract-text/21444699/pubmed\" id=\"21444699\" target=\"_blank\">",
"        21444699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23768/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schaad UB, &ldquo;Role of the New Quinolones in Pediatric Practice,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1992, 11(12):1043-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23768/abstract-text/1461695 /pubmed\" id=\"1461695 \" target=\"_blank\">",
"        1461695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41:1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/13/23768/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16013 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23768=[""].join("\n");
var outline_f23_13_23768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398365\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398376\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398377\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501846\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501924\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8408135\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398378\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398367\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501964\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8404709\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501910\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501903\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8398366\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8401456\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501904\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501907\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501905\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299595\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8401459\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501909\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400751\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8400752\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501965\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501911\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501912\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501967\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11432885\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16013\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16013|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37043?source=related_link\">",
"      Levofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/63/24564?source=related_link\">",
"      Levofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/11/5299?source=related_link\">",
"      Levofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/8/16521?source=related_link\">",
"      Levofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/32/13830?source=related_link\">",
"      Levofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_13_23769="Treatment of the complications of multiple myeloma";
var content_f23_13_23769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of the complications of multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/13/23769/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/13/23769/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/13/23769/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/13/23769/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/13/23769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/13/23769/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/13/23769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple myeloma frequently develop complications related to their disease, including hypercalcemia, renal insufficiency, infection, and skeletal lesions, which require specific treatment in addition to therapy directed at the malignant clone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Some of these problems are discussed in detail elsewhere within UpToDate, but will be briefly reviewed here.",
"   </p>",
"   <p>",
"    The importance of these complications was highlighted in a study of death within 60 days of diagnosis in patients with myeloma entering onto the United Kingdom's Medical Research Council (MRC) trials. The incidence of early death was 10 percent, with the most common contributors being bacterial infection (50 percent) and renal failure (28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of the complications of multiple myeloma will be reviewed here. The uses of chemotherapy and hematopoietic cell transplantation in the treatment of multiple myeloma are discussed separately, as is the diagnosis of multiple myeloma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HYPERCALCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is present in over 10 percent of patients with myeloma at the time of diagnosis and may require emergent treatment. Patients with hypercalcemia may be asymptomatic or complain of a variety of symptoms such as anorexia, nausea, vomiting, polyuria, polydipsia, increased constipation, weakness, confusion, or stupor. Hypercalcemia can also contribute to the development of renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Hypercalcemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most patients with myeloma the diagnosis of hypercalcemia does not require measurement of the ionized calcium. However, if a patient presents with an elevated serum calcium level but no associated symptoms, the ionized calcium should be measured to confirm hypercalcemia prior to the initiation of treatment since rarely the monoclonal protein binds to calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/4\">",
"     4",
"    </a>",
"    ]. The treatment of hypercalcemia depends upon the calcium level, the rapidity with which it developed, and the patient's symptoms. In general, the following approach may be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hydration, preferably with isotonic saline, plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      as part of myeloma therapy or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) is effective in most cases of mild hypercalcemia (eg, serum calcium &lt;12",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"     </li>",
"     <li>",
"      In moderate to severe hypercalcemia (eg, serum calcium &gt;14",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      treatment includes hydration, corticosteroids, and a bisphosphonate such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      . Calcitonin is used if rapid reduction of calcium levels is needed or if patients are refractory to bisphosphonates alone.",
"     </li>",
"     <li>",
"      Extremely severe hypercalcemia (eg, &gt;18",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      may require hemodialysis in addition to the measures outlined above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Typically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    is administered intravenously at a dose of 4 mg over 15 minutes, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    is given intravenously at a dose of 60 to 90 mg over at least two hours. The dose of zoledronic acid needs to be reduced in patients with renal failure. In patients who present with acute and severe renal failure, pamidronate is preferable since the dosing of zoledronic acid may be difficult to determine in the acute setting. Further details regarding the treatment of hypercalcemia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RENAL INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal insufficiency, which can be acute or insidious in onset, occurs in approximately one-half of patients with multiple myeloma. A variety of etiologic mechanisms may be involved, including those related to the excess production of monoclonal light chains (light-chain cast nephropathy), deposition of intact light chains causing nephrotic syndrome (light chain deposition disease), light chain amyloidosis, hypercalcemia, radiocontrast media-induced acute renal failure (usually due to dehydration in the presence of Bence Jones proteinuria) and, infrequently, hyperuricemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients with multiple myeloma, especially those with large amounts of urinary free light chain excretion, should take measures to minimize renal damage. These include the avoidance of nephrotoxins such as aminoglycosides and NSAIDs and the maintenance of hydration by drinking enough fluids to produce 3 liters of",
"    <span class=\"nowrap\">",
"     urine/day.",
"    </span>",
"    Certain medications frequently used for the treatment of multiple myeloma or its complications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ) may require dose adjustment for renal insufficiency or may contribute to renal failure. The treatment of renal insufficiency is directed at the underlying cause, and is discussed elsewhere as is the use of plasmapheresis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemodialysis in the setting of acute renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30409?source=see_link\">",
"     \"Treatment of kidney disease in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of acute renal failure due to light-chain cast nephropathy may also have impact on the choice of initial induction therapy. A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    -containing regimen, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    plus dexamethasone (VD) or bortezomib,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    plus dexamethasone (VTD) may be preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/5\">",
"     5",
"    </a>",
"    ]. This is principally because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (MP) is much less effective in this setting because its effects on the reduction of light chain production are delayed in comparison with treatment programs containing dexamethasone. Further, VD and VTD do not need dose reductions for renal failure. Usually, renal function improves with therapy. Even if it does not, autologous hematopoietic cell transplantation can be performed, but at greater morbidity and mortality in patients with renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H10#H10\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Renal function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with myeloma are at increased risk for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/6\">",
"     6",
"    </a>",
"    ]. The rate of infections is highest in the first three to four months of induction therapy and in the setting of relapsed disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/3\">",
"     3",
"    </a>",
"    ]. Factors that contribute to the increased risk of infection include impaired lymphocyte function, suppression of normal plasma cell function, hypogammaglobulinemia, and chemotherapy induced neutropenia. Pneumonias and urinary tract infections account for the majority infections with Streptococcus pneumoniae, Haemophilus influenza, and Escherichia coli being the most common organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventative measures that may decrease the rate of infection among patients with myeloma include the use of vaccines, prophylactic antibiotics or antivirals, and intravenous immunoglobulin.",
"   </p>",
"   <p>",
"    Patients with myeloma should have yearly influenza vaccines and a single pneumococcal vaccine at the time of diagnosis. Although the antibody response is reduced in many myeloma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], an individual may mount a suboptimal response and still obtain a benefit. Furthermore, there is no evidence that influenza or pneumococcal vaccination is associated with a higher risk of reaction compared to a normal population. Antibody response to pneumococcal vaccination may be suboptimal and prolonged penicillin prophylaxis for pneumococcus should be administered if recurrent pneumococcal infections occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of prophylactic antibiotics is controversial. A prospective study of the value of antimicrobial prophylaxis has completed accrual and results are pending. In clinical practice, we administer routine antibiotic prophylaxis with either a fluoroquinolone (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    500 mg daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) (eg,",
"    <span class=\"nowrap\">",
"     80/400",
"    </span>",
"    mg once daily or",
"    <span class=\"nowrap\">",
"     160/400",
"    </span>",
"    mg every other day) during the first three to four months of chemotherapy. In general, TMP-SMX should be avoided in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    therapy due to increased risk of serious skin toxicity; in these patients a fluoroquinolone is preferable. In addition, for all patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , we administer antiviral prophylaxis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    400 mg twice daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    500 mg once daily) because of the increased risk of herpes zoster (varicella zoster reactivation) with this agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Bortezomib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to administer prophylactic antibiotics at least in the first few months of initial therapy is based upon the high risk of infections in this setting, as well as the results of a small prospective, randomized trial of 54 patients with previously untreated multiple myeloma randomly assigned to treatment with TMP-SMX",
"    <span class=\"nowrap\">",
"     (160/800",
"    </span>",
"    mg PO BID) or placebo for the first two months of induction chemotherapy, which typically included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/10\">",
"     10",
"    </a>",
"    ]. When compared with patients who were assigned to observation, patients assigned to",
"    <span class=\"nowrap\">",
"     TMP/SMX",
"    </span>",
"    had significantly fewer bacterial infections (11 versus 2 patients) and severe infections (8 versus 1 patient) in the first three months. The need for prophylactic antibiotics in the setting of other myeloma therapies (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ) is less clear.",
"   </p>",
"   <p>",
"    Intravenous immune globulin (IGIV, IVIG) may be helpful in selected patients who have recurrent, serious infections despite the use of prophylactic antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H18#H18\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Prevention and management of complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link&amp;anchor=H7#H7\">",
"     \"Immune globulin therapy in primary immunodeficiency\", section on 'Efficacy in preventing infections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link&amp;anchor=H12#H12\">",
"     \"Immune globulin therapy in primary immunodeficiency\", section on 'Administration and dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple myeloma suspected of having an infection should be treated promptly (after obtaining appropriate cultures of blood, urine, chest x-ray, etc.) with empiric antibiotics covering encapsulated bacteria and gram negative microorganisms chosen according to the flora and resistance patterns seen at the institution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with neutropenic fever after chemotherapy may be candidates for prophylactic myeloid growth factors (colony stimulating factors) with subsequent chemotherapy cycles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link&amp;anchor=H523774233#H523774233\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Secondary prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SKELETAL LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal lytic lesions leading to bone pain are present at the time of diagnosis in approximately 60 percent of patients with myeloma and up to 20 percent may have osteopenia. A roentgenographic survey including the skull, spine, pelvis, humeri, and femora is a key component in the diagnosis of myeloma and should be routinely repeated at six-month intervals to monitor for the development of skeletal lesions. Imaging with additional plain films, positron emission tomography (PET),",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    (computed tomography),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging (MRI) is indicated in patients with unexplained bone pain and if pain develops at new sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Radiographic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Avascular necrosis of the femoral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    humeral heads is a rare and usually asymptomatic complication during the treatment of multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/11\">",
"     11",
"    </a>",
"    ]. Cumulative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    dose, male sex, and younger age increase this risk.",
"   </p>",
"   <p>",
"    Vertebral compression fractures are common and can result in decreased total lung capacity and changes in the weight-bearing patterns of the spine potentially leading to more fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prevention of skeletal events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal lesions can result in bone pain, pathologic fractures, and spinal cord compression. All patients with myeloma should be encouraged to be as active as possible in order to maintain bone density while avoiding activities with an excessive risk of trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with one or more lesions on skeletal radiographs and those with osteopenia should be given bisphosphonate therapy, which significantly reduces the number of skeletal events (eg, pathologic fracture, irradiation of or surgery on bone, and spinal cord compression). This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most important complications of prolonged bisphosphonate therapy are acute renal failure (more often with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ), albuminuria (mainly related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    ) and osteonecrosis of the jaw. If these complications occur, either the dose or the frequency of bisphosphonate administration should be decreased or the agent discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is a monoclonal antibody to RANKL (receptor activator of nuclear factor-kappaB ligand) that is used for the treatment of osteoporosis and for the management of bone metastases in the setting of a solid tumor. Randomized phase III trials have compared the efficacy of denosumab versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    in patients with bone lesions in the setting of multiple myeloma or solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. As an example, a phase III trial of 1776 patients with metastatic bone lesions due to multiple myeloma or non-breast, non-prostate solid tumors randomly assigned therapy to denosumab or zoledronic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/12\">",
"     12",
"    </a>",
"    ]. Denosumab and zoledronic acid resulted in similar times to first on-study skeletal-related event and similar survival rates for the group as a whole. However, a post-hoc subset analysis of the 180 patients with multiple myeloma noted higher mortality among those assigned to denosumab therapy (Hazard ratio 2.26; 95% CI 1.13 to 4.50). The suggestion of inferior survival among patients with multiple myeloma treated with denosumab led the US Food and Drug Administration to approve the use of denosumab in patients with bone metastases from solid tumors, but not multiple myeloma. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31737?source=see_link&amp;anchor=H8#H8\">",
"     \"Mechanisms of bone metastases\", section on 'Multiple myeloma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22040?source=see_link\">",
"     \"Denosumab for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=see_link&amp;anchor=H18#H18\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\", section on 'Denosumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment of fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic fractures or impending fractures of long bones require stabilization with an intramedullary rod. Vertebral fractures may benefit from the intralesional injection of a methyl methacrylate cement with kyphoplasty or vertebroplasty. Although the decision to stabilize lytic lesions is made by an orthopedic surgeon and depends upon the location of the lesions, a usual rule of thumb is that if there is 50 percent or more destruction of cortical bone thickness, surgical fixation is required. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Kyphoplasty and vertebroplasty'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pain control",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analgesics and analgesic adjuvants, in combination with chemotherapy, can usually control the bone pain from lytic lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=see_link\">",
"     \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Kyphoplasty and vertebroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertebroplasty involves the percutaneous injection of bone cement (methyl methacrylate) under fluoroscopic guidance into a collapsed vertebral body (VB). Kyphoplasty is a technique that involves the introduction of inflatable bone tamps (KyphX Xpander Balloon, Kyphon, Inc.) into the VB [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/14\">",
"     14",
"    </a>",
"    ]. Once inflated, the bone tamps restore the height of the VB, while creating a cavity that can be filled with viscous bone cement. Kyphoplasty is significantly more expensive than vertebroplasty. The choice between kyphoplasty and vertebroplasty is best dictated by the expertise of the practitioner at each institution [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/7/14458?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures\", section on 'Vertebroplasty and kyphoplasty'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Kyphoplasty and vertebroplasty have been associated with pain relief in prospective trials in patients with myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An international, non-blinded trial randomly assigned treatment with kyphoplasty versus non-surgical management in 134 patients with cancer (37 percent with myeloma) and painful vertebral body compression fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/20\">",
"       20",
"      </a>",
"      ]. In an intention-to-treat analysis, kyphoplasty resulted in a decrease in a back-specific disability measurement at one month. In addition, kyphoplasty was associated with a significantly lower percentage of patients requiring walking aids (46 versus 25 percent), bracing (22 versus 2 percent), bed rest (46 versus 23 percent), and medications of any kind (82 versus 52 percent).",
"     </li>",
"     <li>",
"      In a prospective, uncontrolled study, 55 consecutive kyphoplasty procedures were performed in 18 patients with osteolytic VB compression fractures due to myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/16\">",
"       16",
"      </a>",
"      ]. Significant improvements in pain, physical function, vitality, and social functioning were noted. Pain relief was seen in 80 percent. On average, 34 percent of VB height lost at the time of fracture was restored by this procedure, with no major complications. Asymptomatic cement leakage was noted in 2 of the 55 levels treated.",
"     </li>",
"     <li>",
"      Another report evaluated kyphoplasty and vertebroplasty in a consecutive group of 21 patients with myeloma and 35 with other primary malignancies, all of whom suffered intractable spinal pain secondary to VB fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/17\">",
"       17",
"      </a>",
"      ]. Marked or complete pain relief was achieved in 84 percent; no patient's pain was made worse and there were no deaths or procedure-related complications. Reductions in pain scores remained significant up to one year following the procedures. The mean percent of restored vertebral body height following kyphoplasty was 42 &plusmn; 21 percent. Asymptomatic cement leakage was noted following vertebroplasty or kyphoplasty in 9 and zero percent of cases, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These procedures have never been tested in a blinded trial in myeloma. Two randomized trials of vertebroplasty versus sham vertebroplasty for painful osteoporotic vertebral fractures demonstrated no benefit to vertebroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Patients assigned to vertebroplasty and those assigned to sham vertebroplasty demonstrated similar improvements in pain at night and rest, physical functioning, quality of life, and perceived improvement. &nbsp;",
"   </p>",
"   <p>",
"    In general, the choice between vertebroplasty and kyphoplasty depends on the expertise of the physician performing the procedure. Local radiation therapy is rarely needed after these procedures except in rare cases in which the patient has myeloma refractory to systemic therapy.",
"   </p>",
"   <p>",
"    Short-term complications occur predominantly due to extravasation of the cement and may include increased pain and damage from heat or pressure to the spinal cord or nerve roots, and rarely cement embolization. Patients thought to be most likely to benefit are those who have pain that anatomically correlates to the area of fracture and is most severe in the upright position (eg, standing or walking) and decreases in the reclining position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 40 percent of patients with myeloma will require radiation to control disease at some point in their disease course [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/23\">",
"     23",
"    </a>",
"    ]. Common indications for radiation therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain control of lytic lesions that are refractory to systemic therapy.",
"     </li>",
"     <li>",
"      Treatment of spinal cord compression from plasmacytoma. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cord compression'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Primary treatment of solitary plasmacytoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44535?source=see_link\">",
"       \"Diagnosis and management of solitary plasmacytoma of bone\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16662?source=see_link\">",
"       \"Diagnosis and management of solitary extramedullary plasmacytoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Post-surgical radiation after stabilization of impending fractures is rarely needed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/24\">",
"     24",
"    </a>",
"    ]. Extensive radiation should be avoided because it can reduce bone marrow reserve, compromise future chemotherapy, and may prevent a future autologous stem cell procedure. Most patients can get equally rapid pain relief and reduction in tumor mass with systemic therapy for myeloma. The dose of radiation used varies according to the clinical situation. Palliation of lytic bone lesions may be accomplished with 20 to 30 Gy administered in 5 to 10 fractions while higher doses are required for the treatment of solitary plasmacytoma (in which the intent is curative) or spinal cord compression. Whether radiation is more effective when given in conjunction with chemotherapy is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Cord compression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are limited data regarding the ideal dose of palliative radiation for bone lesions. A retrospective single institution study of 101 patients administered palliative radiation to 306 symptomatic bone sites reported at least partial symptom relief in 98 percent of sites receiving 10 or greater Gy of radiation with no dose response demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/25\">",
"     25",
"    </a>",
"    ]. A minority of sites had complete symptom control (26 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cord compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord compression from an extramedullary plasmacytoma or retropulsed bone should be suspected in patients with severe back pain, weakness, or paresthesias of the lower extremities, or bladder or bowel dysfunction or incontinence. Magnetic resonance imaging (MRI) or computed tomographic (CT) myelography of the entire spine must be performed",
"    <strong>",
"     immediately",
"    </strong>",
"    if this complication is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prompt diagnosis and immediate treatment are critically important in the preservation of neurological function in patients with spinal cord compression. The goals of treatment include pain control, avoidance of complications, and the preservation or improvement of neurologic functioning. In patients with neurologic symptoms directly due to cord compression, radiation therapy is given along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and up to half of patients may have improvement of motor function with radiotherapy with longer fractionation schedules providing better relief [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/26\">",
"     26",
"    </a>",
"    ]. Systemic therapy with regimens such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , dexamethasone (VCD) or bortezomib,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , dexamethasone (VTD) work rapidly and can be used instead of radiation in selected patients if there is minimal neurologic deficit. Surgical decompression is necessary only if the neurologic deficit does not improve or if the compression is due to retropulsed bone. Details regarding the treatment of neoplastic spinal cord compression are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=see_link\">",
"     \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority (97 percent) of patients with myeloma will have anemia (hemoglobin &le;12",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    at some time during the course of the disease. The initial evaluation of anemia in a patient with myeloma should include a search for common causes of anemia in patients without myeloma (eg, iron or vitamin deficiencies). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of anemia associated with myeloma depends upon the severity of the anemia, the presence or absence of symptoms related to anemia, and whether the patient is undergoing active chemotherapy. Patients with significant symptoms should be considered for red blood cell transfusion. If a transfusion is indicated, irradiated, leukoreduced cross-matched red cells are preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to use erythropoiesis-stimulating agents (ESAs) for anemia in multiple myeloma is based upon a number of factors, including stage of disease, response to anti-myeloma therapy, serum erythropoietin levels, cost, and reimbursement policies (eg, need for physician administration). In addition, the use of ESAs is a risk factor for the development of venous thromboembolism among patients with myeloma, especially those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/27\">",
"     27",
"    </a>",
"    ]. In patients with newly diagnosed myeloma, induction chemotherapy with a good disease response is usually associated with a prompt improvement in hemoglobin levels, and it is better to avoid the use of ESAs. ESAs are generally reserved for patients receiving chemotherapy with a hemoglobin level of 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or less. The typical dosage is erythropoietin 40,000 units once a week or darbepoetin 200 micrograms every two to three weeks. Darbepoetin has an advantage when physician administration is required. More information on the",
"    <span class=\"nowrap\">",
"     ASH/ASCO",
"    </span>",
"    guidelines and suggested starting doses can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H2#H2\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Overview of treatment options for anemia in cancer patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized placebo-controlled trials have shown that symptomatic anemia during the plateau phase of multiple myeloma is often improved by the administration of erythropoietin (EPO) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In one randomized trial, 145 patients with multiple myeloma and a hemoglobin concentration &lt;11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    were treated with either 150",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    of EPO or a matching volume of placebo subcutaneously three times a week for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/30\">",
"     30",
"    </a>",
"    ]. The dose was doubled at week four if the hemoglobin response was inadequate.",
"   </p>",
"   <p>",
"    During the double-blind phase of the study, patients receiving EPO had a significantly lower incidence of transfusion (28 versus 47 percent) and larger increase in hemoglobin concentration (1.8 versus 0.0",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"    During the open label portion of the trial, patients initially receiving placebo who were switched to EPO had a mean increase in hemoglobin concentration of 2.4",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HYPERVISCOSITY SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients with multiple myeloma develop the hyperviscosity syndrome. This syndrome is characterized by oronasal bleeding, blurred vision, neurologic symptoms, confusion, and heart failure. Serum viscosity measurements do not correlate well with symptoms or the clinical findings. Plasmapheresis promptly relieves the symptoms and should be performed regardless of the viscosity level if the patient is symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link&amp;anchor=H5#H5\">",
"     \"Prescription and technique of therapeutic plasma exchange\", section on 'Apheresis schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple myeloma or the precursor lesion monoclonal gammopathy of undetermined significance (MGUS) have an increased incidence of venous thromboembolism (VTE). In addition, a few studies have suggested an increased risk of arterial thromboembolism (ATE) in these populations as manifested by stroke, transient ischemic attack, myocardial infarction, or symptomatic peripheral artery disease. These increased rates appear to be both a result of the malignancy itself and the therapy given (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    -based regimens).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A population-based study of over 4 million patients receiving care at US Veterans Affairs hospitals reported rates of VTE among patients with MM or MGUS of approximately 8.7 and 3.1 cases per 1000 person-years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Population-based data from Sweden comparing persons with MM or MGUS with matched controls demonstrated that patients with MM and MGUS had increased risks of VTE and ATE in the first 10 years after diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/33\">",
"       33",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The increase in risk of VTE was highest for patients with MM in the first year after diagnosis (hazard ratio [HR] 7.5, 95% CI 6.4-8.9).",
"     </li>",
"     <li>",
"      Patients with MM also had an increased risk of ATE in the first year (HR 1.9, 95% CI 1.8-2.1).",
"     </li>",
"     <li>",
"      Patients with MGUS demonstrated increased risks of VTE and ATE, but the magnitude of effect was smaller.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective trial in 195 consecutive patients with newly diagnosed MM treated with three cycles of chemotherapy followed by high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      and autologous hematopoietic cell transplantation reported a higher than expected frequency of ATE [",
"      <a class=\"abstract\" href=\"UTD.htm?23/13/23769/abstract/34\">",
"       34",
"      </a>",
"      ]. Induction chemotherapy included",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      (VAD),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (TAD), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      (PAD). Eleven patients developed ATE, six of which occurred during induction chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues related to the treatment of VTE, the risk of VTE with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    analogs, and the use of VTE prophylaxis with thalidomide analogs are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/26/29090?source=see_link\">",
"       \"Patient information: Multiple myeloma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common complications of multiple myeloma include hypercalcemia, renal insufficiency, infection, skeletal lesions, and anemia. Less common complications include venous thromboembolism and the hyperviscosity syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypercalcemia &mdash; Patients with hypercalcemia may be asymptomatic or present with anorexia, nausea, vomiting, polyuria, polydipsia, constipation, weakness, confusion, or stupor. The treatment of hypercalcemia depends upon the calcium level, the rapidity with which it developed, and the patient's symptoms. Emergent treatment with hydration, glucocorticoids, bisphosphonates,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       hemodialysis/calcitonin",
"      </span>",
"      is indicated for symptomatic patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hypercalcemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"       \"Treatment of hypercalcemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal insufficiency &mdash; All patients with multiple myeloma should take measures to minimize renal damage (eg, avoid nephrotoxins such as aminoglycosides and NSAIDs and maintain adequate hydration). Many medications used for myeloma require dose adjustment for renal insufficiency (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      ). Treatment of renal insufficiency is directed at the underlying cause. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Renal insufficiency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30409?source=see_link\">",
"       \"Treatment of kidney disease in multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infection &mdash; Prophylactic measures that may minimize infection in patients with myeloma include yearly influenza vaccines, pneumococcal vaccine at the time of diagnosis, prophylactic antibiotics during the first months of induction chemotherapy, and intravenous immune globulin for selected patients who have recurrent, serious infections. Patients suspected of having an infection should be treated promptly with empiric antibiotics covering encapsulated bacteria and gram negative microorganisms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Infection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"       \"Immunizations in patients with cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"       \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skeletal lesions &mdash; Physical activity should be encouraged in order to maintain bone density, but requires adequate pain control. Patients with one or more lesions on skeletal radiographs and those with osteopenia are candidates for bisphosphonate therapy to prevent skeletal events. Pathologic fractures or impending fractures of long bones require stabilization with an intramedullary rod. Vertebral fractures may benefit from kyphoplasty or vertebroplasty. Most pain related to lytic lesions can be controlled with the combination of analgesics and active myeloma chemotherapy. Spinal cord compression is a clinical emergency and should be suspected in patients with severe back pain, weakness, or paresthesias of the lower extremities, or bladder or bowel dysfunction or incontinence. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Skeletal lesions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=see_link\">",
"       \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia &mdash; The treatment of anemia associated with myeloma depends upon the severity of the anemia, the presence or absence of symptoms related to anemia, and whether the patient is undergoing active chemotherapy. Patients with significant symptoms should be considered for red blood cell transfusion. Erythropoiesis-stimulating agents are generally reserved for patients receiving chemotherapy with a hemoglobin level of 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or less. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Anemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"       \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/1\">",
"      Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/2\">",
"      Smith A, Wisloff F, Samson D, et al. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006; 132:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/3\">",
"      Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23:9219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/4\">",
"      Annesley TM, Burritt MF, Kyle RA. Artifactual hypercalcemia in multiple myeloma. Mayo Clin Proc 1982; 57:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/5\">",
"      Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 2011; 364:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/6\">",
"      Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009; 49:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/7\">",
"      Rapezzi D, Sticchi L, Racchi O, et al. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. Eur J Haematol 2003; 70:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/8\">",
"      Robertson JD, Nagesh K, Jowitt SN, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 2000; 82:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/9\">",
"      Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 2005; 130:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/10\">",
"      Oken MM, Pomeroy C, Weisdorf D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996; 100:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/11\">",
"      Talamo G, Angtuaco E, Walker RC, et al. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. J Clin Oncol 2005; 23:5217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/12\">",
"      Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/13\">",
"      Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/14\">",
"      Hussein MA, Vrionis FD, Allison R, et al. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia 2008; 22:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/15\">",
"      McDonald RJ, Gray LA, Cloft HJ, et al. The effect of operator variability and experience in vertebroplasty outcomes. Radiology 2009; 253:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/16\">",
"      Dudeney S, Lieberman IH, Reinhardt MK, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 2002; 20:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/17\">",
"      Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 2003; 98:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/18\">",
"      Lane JM, Hong R, Koob J, et al. Kyphoplasty enhances function and structural alignment in multiple myeloma. Clin Orthop Relat Res 2004; :49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/19\">",
"      Hentschel SJ, Burton AW, Fourney DR, et al. Percutaneous vertebroplasty and kyphoplasty performed at a cancer center: refuting proposed contraindications. J Neurosurg Spine 2005; 2:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/20\">",
"      Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol 2011; 12:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/21\">",
"      Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med 2009; 361:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/22\">",
"      Kallmes DF, Comstock BA, Heagerty PJ, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med 2009; 361:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/23\">",
"      Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma. Cancer 2005; 103:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/24\">",
"      Lecouvet F, Richard F, Vande Berg B, et al. Long-term effects of localized spinal radiation therapy on vertebral fractures and focal lesions appearance in patients with multiple myeloma. Br J Haematol 1997; 96:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/25\">",
"      Leigh BR, Kurtts TA, Mack CF, et al. Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys 1993; 25:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/26\">",
"      Rades D, Hoskin PJ, Stalpers LJ, et al. Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. Int J Radiat Oncol Biol Phys 2006; 64:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/27\">",
"      Anaissie EJ, Coleman EA, Goodwin JA, et al. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer 2012; 118:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/28\">",
"      Garton JP, Gertz MA, Witzig TE, et al. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 1995; 155:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/29\">",
"      Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996; 87:2675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/30\">",
"      Dammacco F, Castoldi G, R&ouml;djer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001; 113:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/31\">",
"      Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intensive Care Med 1995; 10:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/32\">",
"      Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008; 112:3582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/33\">",
"      Kristinsson SY, Pfeiffer RM, Bj&ouml;rkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010; 115:4991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/13/23769/abstract/34\">",
"      Libourel EJ, Sonneveld P, van der Holt B, et al. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood 2010; 116:22.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6664 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23769=[""].join("\n");
var outline_f23_13_23769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HYPERCALCEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SKELETAL LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prevention of skeletal events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment of fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pain control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Kyphoplasty and vertebroplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cord compression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HYPERVISCOSITY SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=related_link\">",
"      Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/7/14458?source=related_link\">",
"      Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22040?source=related_link\">",
"      Denosumab for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16662?source=related_link\">",
"      Diagnosis and management of solitary extramedullary plasmacytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44535?source=related_link\">",
"      Diagnosis and management of solitary plasmacytoma of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=related_link\">",
"      Diagnostic approach to the adult presenting with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31737?source=related_link\">",
"      Mechanisms of bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/26/29090?source=related_link\">",
"      Patient information: Multiple myeloma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=related_link\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=related_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30409?source=related_link\">",
"      Treatment of kidney disease in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_13_23770="Gonorrhea and penile discharge";
var content_f23_13_23770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77674%7EDERM%2F68498%7EDERM%2F54221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77674%7EDERM%2F68498%7EDERM%2F54221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Penile discharge in gonorrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute gonorrhea. A purulent discharge emanates from the urethra.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gonorrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 23-year-old man complained of profuse and purulent penile discharge with dysuria five days after unprotected sexual contact. Gram stain of the urethral discharge showed polymorphonuclear cells with intracellular Gram negative diplococci.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; SV Rakhesh, MD, Dermatlas;",
"     <a href=\"file://www.dermatlas.org\" target=\"_blank\">",
"      file://www.dermatlas.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Penile edema in gonorrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 2-year-old boy developed a urethral discharge (positive for Neisseria gonorrhoeae), followed by painless swelling of the distal penile shaft. This condition is more common in adolescent and young adult males.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23770=[""].join("\n");
var outline_f23_13_23770=null;
var title_f23_13_23771="Cytokines and fibroblasts";
var content_f23_13_23771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effect of cytokines on fibroblast collagen metabolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Fibroblast response",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mediators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased fibroblast chemotaxis",
"       </td>",
"       <td>",
"        TGF-beta, IL-4, TNF-alpha and beta, PDGF, IFN gamma, ET-1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased fibroblast proliferation",
"       </td>",
"       <td>",
"        IL-1 alpha and beta, bFGF, aFGF, PDGF, IL-6, EGF, TGF-beta (via PDGF), ET-1, IL-17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased collagen synthesis",
"       </td>",
"       <td>",
"        TGF-&beta;, IL-1 alpha and beta, IL-4, IGF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased collagen synthesis",
"       </td>",
"       <td>",
"        bFGF, IFN gamma and alpha, relaxin, EGF, TNF-alpha",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased collagenase synthesis",
"       </td>",
"       <td>",
"        IL-1 alpha and beta, bFGF, TNF-alpha and beta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased collagen synthesis",
"       </td>",
"       <td>",
"        TGF-beta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased TIMP synthesis",
"       </td>",
"       <td>",
"        IL-1 alpha and beta, TGF-beta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased TIMP synthesis",
"       </td>",
"       <td>",
"        IL-6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23771=[""].join("\n");
var outline_f23_13_23771=null;
var title_f23_13_23772="DDx horizontal gaze palsy";
var content_f23_13_23772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Localization of lesions causing horizontal gaze palsy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Frontal lobe lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Defect in generating voluntary saccades",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient ipsilateral horizontal gaze deviation acutely",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gaze palsy overcome with the oculocephalic (doll's eye) maneuver or caloric stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Epileptogenic lesions in the frontal eye fields",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient deviation of the eyes and head to the contralateral side",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head and eye movements toward the same side during a seizure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Unilateral parietal lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unilateral or bilateral increased saccade latencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypometria (shortened range) for contralateral saccades",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Saccadic slowing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bilateral parietal lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acquired ocular motor apraxia (inability to generate voluntary movements)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lesions in the corona radiata adjacent to the genu of the internal capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contralateral selective saccadic palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hemorrhages deep in a cerebral hemisphere, particularly the thalamus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eye deviation to the side of the hemiparesis (\"wrong-way eyes\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mesencephalic lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paresis of contralateral saccades",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supranuclear contralateral gaze palsies associated with ipsilateral oculomotor palsies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pontine lesions affecting the abducens nucleus and/or the PPRF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ipsilateral conjugate gaze palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doll's eye maneuver or cold caloric stimulation usually does not overcome gaze palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral horizontal gaze palsies with bilateral lesions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Lee AG, Brazis PW. Clinical Pathways in Neuro-ophthalmology: An Evidence-based Approach, Thieme, New York 1998.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23772=[""].join("\n");
var outline_f23_13_23772=null;
var title_f23_13_23773="2010 TNM staging STS";
var content_f23_13_23773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging for soft tissue sarcoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"4\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"4\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"4\">",
"       Tumor 5 cm or less in greatest dimension*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1a",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"4\">",
"       Superficial tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1b",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"4\">",
"       Deep tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T2",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"4\">",
"       Tumor more than 5 cm in greatest dimension*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T2a",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"4\">",
"       Superficial tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T2b",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"4\">",
"       Deep tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"4\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"4\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1&bull;",
"      </td>",
"      <td colspan=\"4\">",
"       Regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"4\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"4\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Histologic grade (G)&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       GX",
"      </td>",
"      <td colspan=\"4\">",
"       Grade cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G1",
"      </td>",
"      <td colspan=\"4\">",
"       Grade 1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G2",
"      </td>",
"      <td colspan=\"4\">",
"       Grade 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G3",
"      </td>",
"      <td colspan=\"4\">",
"       Grade 3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IA",
"      </td>",
"      <td>",
"       T1a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       G1, GX",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       G1, GX",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IB",
"      </td>",
"      <td>",
"       T2a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       G1, GX",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       G1, GX",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IIA",
"      </td>",
"      <td>",
"       T1a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       G2, G3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       G2, G3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IIB",
"      </td>",
"      <td>",
"       T2a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       G2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       G2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage III",
"      </td>",
"      <td>",
"       T2a, T2b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       G3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any G",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IV",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"      <td>",
"       Any G",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Superficial tumor is located exclusively above the superficial fascia without invasion of the fascia; deep tumor is located either exclusively beneath the superficial fascia, superficial to the fascia with invasion of or through the fascia, or both superficial yet beneath the fascia.",
"     <br>",
"      &bull; Presence of positive nodes (N1) in M0 tumors is considered Stage III.",
"      <br>",
"       &Delta; FNCLCC System preferred.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23773=[""].join("\n");
var outline_f23_13_23773=null;
var title_f23_13_23774="Propranolol after acute MI";
var content_f23_13_23774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Benefit of propranolol after myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results of the Beta Blocker Heart Attack Trial which randomized 3837 patients with an acute myocardial infarction to propranolol or placebo. At an average follow-up of 25 months, propranolol significantly reduced total, cardiovascular, and sudden death mortality and reduced the incidence of nonfatal infarction and all coronary events. Benefit occurred in all patient groups, but was more marked in those with heart failure (HF).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Chadda K, Goldstein S, Byington R, et al. Circulation 1986; 73:503.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23774=[""].join("\n");
var outline_f23_13_23774=null;
var title_f23_13_23775="Pathogenesis of CRC";
var content_f23_13_23775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathogenesis of colorectal cancer: adenoma-carcinoma sequence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from O'Brien, MJ, Winawer, SJ, Waye, JB. Colorectal polyps. In: Management of Gastrointestinal Diseases, Winawer, SJ (Ed). Gower Medical, New York, 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_13_23775=[""].join("\n");
var outline_f23_13_23775=null;
